drugset
drugset / Trial / NCT01617057

Therapeutic Efficacy of Tiludronic Acid on Inner Ear Involvement in Advanced Otosclerosis

NCT01617057 ↗

Phase 3 Terminated 31 enrolled Assistance Publique - Hôpitaux de Paris
RandomizedParallel-groupTriple-blindTreatment

Summary

The aim of this study is to assess the efficacy of a biphosphonate (tiludronic acid, Skelid®, Sanofi-Aventis) in the treatment of inner ear involvement in advanced otosclerosis

Timeline

Start
2012-05
Primary completion
2016-03
Completion
2017-07

Outcome

Outcome not reported

Stopped: “lack of inclusion”

Drugs

EvaluationDrugModalityDoseRoute
Subject tiludronic acid Small molecule 400 mg —

Indications

otosclerosis